World Diabetes Day Tomorrow: New data in UAE announcing cure for diabetes

Program leads to remission of Type 2 diabetes with a reduction in average hemoglobin A1c of 1.5% combined with average Total Body Weight Loss of 16.2% after just 4 months
 
Allurion Technologies, a company dedicated to ending obesity, announced new clinical data on the Allurion Program as an emerging novel treatment for Type 2 diabetes and prediabetes, presented at ObesityWeek® 2021. The program, which is available across clinics in the United Arab Emirates, has been clinically proven to treat patients living with these conditions, bringing them into disease remission.
 
  • Despite the availability of pharmacologic therapies for Type 2 diabetes, the incidence of the metabolic disease continues to rise around the world.
  • 537 million adults are now living with diabetes worldwide, an increase of 16% (74 million people) since 2019.
  • By 2045, about 783 million people, or one in eight adults, will be living with diabetes worldwide, indicating that current treatment options are not sufficient.
  • Additionally, diabetes is not only increasing globally but at a much faster rate in regions such as the UAE, where the population with diabetes is projected to increase to about 2.2 million by 2040 (*further insights in release)
I have also attached a snapshot of the release below for ease (full release attached) and we have access to Dr. Shantanu Gaur, the co-founder and CEO of Allurion Technologies should he be of interest for an interview for Web-Release.info.
 
Dr. Shantanu Gaur, co-founder and CEO Allurion, said Allurion’s mission is to act as a catalyst to end obesity and the resulting effects from the disease, including diabetes. “Obesity and Type 2 diabetes are pandemics of unprecedented magnitude, and they often afflict patients simultaneously,” Gaur said. “Current treatments for obesity and diabetes either suffer from poor safety and efficacy or a poor patient experience. The Allurion Program offers a compelling alternative for the treatment of both of these conditions.”

Comments are closed.

Web Release